Overview

The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)

Status:
Recruiting
Trial end date:
2021-09-15
Target enrollment:
Participant gender:
Summary
Multicenter study to evaluate the safety and tolerability in patients with wet Age-related macular degeneration (wAMD) treated with intravitreal recombinant humanized anti-VEGF monoclonal antibody
Phase:
Phase 1
Details
Lead Sponsor:
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.